Platform Technology Partners Acquires 2,136 Shares of Johnson & Johnson $JNJ

Platform Technology Partners lifted its holdings in Johnson & Johnson (NYSE:JNJ) by 9.1% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 25,544 shares of the company’s stock after acquiring an additional 2,136 shares during the period. Johnson & Johnson accounts for approximately 1.2% of Platform Technology Partners’ holdings, making the stock its 18th biggest holding. Platform Technology Partners’ holdings in Johnson & Johnson were worth $6,244,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in the stock. Sound Income Strategies LLC raised its position in Johnson & Johnson by 1.4% during the first quarter. Sound Income Strategies LLC now owns 5,881 shares of the company’s stock valued at $1,436,000 after purchasing an additional 82 shares during the period. Jamison Private Wealth Management Inc. increased its position in Johnson & Johnson by 0.6% during the first quarter. Jamison Private Wealth Management Inc. now owns 88,262 shares of the company’s stock valued at $21,575,000 after acquiring an additional 536 shares during the last quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. raised its stake in shares of Johnson & Johnson by 34.5% in the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 113,380 shares of the company’s stock valued at $27,715,000 after acquiring an additional 29,080 shares during the period. SOL Capital Management CO raised its position in Johnson & Johnson by 21.8% in the 1st quarter. SOL Capital Management CO now owns 9,228 shares of the company’s stock worth $2,256,000 after purchasing an additional 1,652 shares during the period. Finally, Patten Group Inc. lifted its stake in Johnson & Johnson by 1.7% in the first quarter. Patten Group Inc. now owns 22,839 shares of the company’s stock worth $5,583,000 after purchasing an additional 381 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have recently commented on JNJ shares. TD Cowen started coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They set a “buy” rating and a $250.00 target price on the stock. The Goldman Sachs Group increased their target price on Johnson & Johnson from $265.00 to $275.00 and gave the stock a “buy” rating in a research note on Wednesday, April 15th. Bank of America boosted their target price on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a “neutral” rating in a research note on Wednesday, April 15th. Daiwa Securities Group raised their price target on shares of Johnson & Johnson from $237.00 to $246.00 and gave the stock an “outperform” rating in a research note on Thursday, April 16th. Finally, Wells Fargo & Company lifted their price objective on shares of Johnson & Johnson from $240.00 to $263.00 and gave the company an “overweight” rating in a report on Wednesday, April 15th. Twenty equities research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus target price of $256.70.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Members of Congress have been buying J&J shares, which can signal confidence in the company’s prospects and may attract attention from retail investors. Members of Congress Are Loading Up on Johnson & Johnson and UnitedHealth. Here’s Why Retail Investors Should Pay Attention.
• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation platform in Europe, adding a commercial growth catalyst in its medtech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: J&J is being highlighted as a top dividend and defensive healthcare name, with articles pointing to its reliable cash flow, dividend profile, and long-term appeal. Johnson & Johnson (JNJ): Focused on Cancer and Neuroscience as a Top Dividend Aristocrat Stock to Buy
• Positive Sentiment: Recent updates say J&J is strengthening its cancer pipeline, including European progress for Tecvayli in combination with Darzalex and an acquisition of Firefly Bio to expand oncology research. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Neutral Sentiment: Several market commentary pieces reiterated bullish Wall Street views and compared J&J favorably with AbbVie, supporting the stock’s valuation narrative but not adding a major new catalyst. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: J&J was also featured in dividend-income and portfolio articles, which helps reinforce its reputation as a stable income stock, though these pieces are unlikely to move shares much on their own. J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?
• Negative Sentiment: No major negative company-specific headline stood out in the latest set of articles; the closest risk item is that ongoing litigation remains a background concern, even as one recent talc verdict went J&J’s way. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of JNJ stock opened at $262.52 on Monday. The stock has a market capitalization of $631.93 billion, a price-to-earnings ratio of 30.35, a P/E/G ratio of 2.58 and a beta of 0.24. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a twelve month low of $154.21 and a twelve month high of $263.10. The stock has a fifty day simple moving average of $233.72 and a two-hundred day simple moving average of $231.37.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm’s quarterly revenue was up 9.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, analysts predict that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. Johnson & Johnson’s payout ratio is presently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.